Genedrive PLC Equity Prepayment Facility drawdown (5269B)
02 June 2023 - 9:25PM
UK Regulatory
TIDMGDR
RNS Number : 5269B
Genedrive PLC
02 June 2023
genedrive plc
("genedrive" or the "Company")
Equity Prepayment Facility drawdown
genedrive plc (LSE: GDR), the point of care molecular
diagnostics company, today announces a first GBP300,000 draw down
under the terms of the GBP5m Equity Prepayment Facility, which was
previously announced by the Company on 31 March 2023. Investors
have been granted 682,730 warrants equal to 40% of this drawdown
divided by the Reference Price of 17.57648 pence. The exercise
price of the warrants payable to the Company will be 140% of the
Reference Price equating to 24.6071 pence.
Capitalised terms in this announcement shall, unless the context
demands otherwise, bear the meanings given to such terms in the
announcement of the Facility made via RNS on 31 March 2023.
For further information, please contact:
genedrive plc +44 (0) 161 989 0245
David Budd (CEO) / Russ Shaw
(CFO)
Peel Hunt LLP - Nominated Adviser,
Joint Broker +44 (0) 20 7148 8900
James Steel / Oliver Duckworth
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / George Dollemore
Walbrook PR - Financial PR & IR
Adviser +44 (0) 20 7933 8780
Paul McManus / Anna Dunphy Or Genedrive@walbrookpr.com
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The company are currently developing a genetic test
for CYP2C19 metaboliser status.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUPPQUPWGGP
(END) Dow Jones Newswires
June 02, 2023 07:25 ET (11:25 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024